Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3605-3611

  Ebert, Oliver ^a   Shinozaki, Katsunori ^a   Huang, Tian Gui ^a   Savontaus, Mikko J ^a,b   García Sastre, Adolfo ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; LIVER CELL CARCINOMA; LIVER CELL CULTURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RNA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS ATTENUATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED BUF; RECOMBINATION, GENETIC; RNA, VIRAL; TUMOR CELLS, CULTURED; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

EID: 0038756431     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 94: 153-156, 2001.
2. Murray, C. J., and Lopez, A. D. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science (Wash. DC), 274: 740-743, 1996.
3. Parkin, D. M., Stjernsward, J., and Muir, C. S. Estimates of the worldwide frequency of twelve major cancers. Bull. W. H. O., 62: 163-182, 1984.
4. Fong, Y., Sun, R. L., Jamagin, W., and Blumgart, L. H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann. Surg., 229: 790-799, 1999.
5. Schwartz, M. E., Sung, M., Mor, E., Fisher, A., Popescu, I., Fiel, I., Sheiner, P., Emre, S., Guy, S., and Miller, C. M. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J. Am. Coll. Surg., 180: 596-603, 1995.
6. Selby, R., Kadry, Z., Carr, B., Tzakis, A., Madariaga, J. R., and Iwatsuki, S. Liver transplantation for hepatocellular carcinoma. World J. Surg., 19: 53-58, 1995.
7. Kirn, D., Martuza, R. L., and Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med., 7: 781-787, 2001.
8. Letchworth, G. J., Rodriguez, L. L., and Del, C. Barrera, J. Vesicular stomatitis. Vet. J., 157: 239-260, 1999.
9. Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., and Bell, J. C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med., 6: 821-825, 2000.
10. Stojdl, D. F., Abraham, N., Knowles, S., Marius, R., Brasey, A., Lichty, B. D., Brown, E. G., Sonenberg, N., and Bell, J. C. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol., 74: 9580-9585, 2000.
11. Lawson, N. D., Stillman, E. A., Whitt, M. A., and Rose, J. K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA, 92: 4477-4481, 1995.
12. Whelan, S. P., Ball, L. A., Barr, J. N., and Wertz, G. T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA, 92: 8388-8392, 1995.
13. Schnell, M. J., Buonocore, L., Kretzschmar, E., Johnson, E., and Rose, J. K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA, 93: 11359-11365, 1996.
14. Schnell, M. J., Buonocore, L., Whitt, M. A., and Rose, J. K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol., 70: 2318-2323, 1996.
15. Boritz, E., Gerlach, J., Johnson, J. E., and Rose, J. K. Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. J. Virol., 73: 6937-6945, 1999.
16. Melen, K., Keskinen, P., Lehtonen, A., and Julkunen, I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J. Hepatol., 33: 764-772, 2000.
17. Keskinen, P., Nyqvist, M., Sareneva, T., Pirhonen, J., Melen, K., and Julkunen, I. Impaired antiviral response in human hepatoma cells. Virology, 263: 364-375, 1999.
18. Williams, B. R. PKR, a sentinel kinase for cellular stress. Oncogene, 18: 6112-6120, 1999.
19. Bergmann, M., Romirer, I., Sachet, M., Fleischhacker, R., Garcia-Sastre, A., Palese, P., Wolff, K., Pehamberger, H., Jakesz, R., and Muster, T. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res., 61: 8188-8193, 2001.
20. Farassati, F., Yang, A. D., and Lee, P. W. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol., 3: 745-750, 2001.
21. Lorence, R. M., Katubig, B. B., Reichard, K. W., Reyes, H. M., Phuangsab, A., Sassetti, M. D., Walter, R. J., and Peeples, M. E. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res., 54: 6017-6021, 1994.
22. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. Reovirus therapy of tumors with activated Ras pathway. Science (Wash. DC), 282: 1332-1334, 1999.
23. Balachandran, S., Porosnicu, M., and Barber, G. N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol., 75: 3474-3479, 2001.
24. Fernandez, M., Porosnicu, M., Markovic, D., and Barber, G. N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol., 76: 895-904, 2002.
25. Charan, S., and Zinkernagel, R. M. Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus. J. Immunol., 136: 3057-3061, 1986.
26. Kundig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkemagel, R. M., and Horak, I. Immune responses in interleukin-2-deficient mice. Science (Wash. DC), 262: 1059-1061, 1993.
27. Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, I. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R. t., Louis, D. N., Bartus, R. T., Hochberg, F. H., and Chiocca, E. A. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med., 5: 881-887, 1999.
28. Todo, T., Rabkin, S. D., Sundaresan, P., Wu, A., Meehan, K. R., Herscowitz, H. B., and Martuza, R. L. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther., 10: 2741-2755, 1999.
29. Steinhauer, D. A., de la Torre, J. C., and Holland, J. J. High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus. J. Virol., 63: 2063-2071, 1989.